Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insmed's Total Operating Expense for the
three
months ended in Jun. 2026 was MXN8,019 Mil. Insmed's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN31,610 Mil.
The historical data trend for Insmed's Total Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.
Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN31,610 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Operating Expense of MXN31,610 Mil mean?
Insmed (MEX:INSM) has a Total Operating Expense of MXN31,610 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Insmed and its competitors.
Is Insmed's Total Operating Expense too high?
Insmed's current Total Operating Expense is MXN31,610 Mil. Overall, Insmed has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Total Operating Expense compare to INCY and BNTX?
Insmed's Total Operating Expense of MXN31,610 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Insmed and its competitors. Insmed's current Total Operating Expense is MXN31,610 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN6,955.50, compared to a current price of MXN2,135.00 — trading 69.3% below its estimated fair value. The current Total Operating Expense is MXN31,610 Mil. Insmed's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Total Operating Expense is MXN31,610 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN2,135.00 is trading 69.3% below its estimated GF Value™ of MXN6,955.50.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MEX:INSM:
Total Operating Expense: MXN31,610 Mil
GF Value™: MXN6,955.50 vs. price of MXN2,135.00 (69.3% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
73GF Score
Get the complete analysis for MEX:INSM
Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
